BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24335344)

  • 1. Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy.
    Meregalli C; Chiorazzi A; Carozzi VA; Canta A; Sala B; Colombo M; Oggioni N; Ceresa C; Foudah D; La Russa F; Miloso M; Nicolini G; Marmiroli P; Bennett DL; Cavaletti G
    Cell Cycle; 2014; 13(4):612-21. PubMed ID: 24335344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons.
    Staff NP; Podratz JL; Grassner L; Bader M; Paz J; Knight AM; Loprinzi CL; Trushina E; Windebank AJ
    Neurotoxicology; 2013 Dec; 39():124-31. PubMed ID: 24035926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect.
    Malacrida A; Semperboni S; Di Domizio A; Palmioli A; Broggi L; Airoldi C; Meregalli C; Cavaletti G; Nicolini G
    Sci Rep; 2021 May; 11(1):10523. PubMed ID: 34006972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNF-α-mediated JNK activation in the dorsal root ganglion neurons contributes to Bortezomib-induced peripheral neuropathy.
    Zhang J; Su YM; Li D; Cui Y; Huang ZZ; Wei JY; Xue Z; Pang RP; Liu XG; Xin WJ
    Brain Behav Immun; 2014 May; 38():185-91. PubMed ID: 24530998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.
    Alé A; Bruna J; Morell M; van de Velde H; Monbaliu J; Navarro X; Udina E
    Exp Neurol; 2014 Mar; 253():165-73. PubMed ID: 24406455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association of Neuronal Stress with Activating Transcription Factor 3 in Dorsal Root Ganglion of in vivo and in vitro Models of Bortezomib- Induced Neuropathy.
    Yin Y; Qi X; Qiao Y; Liu H; Yan Z; Li H; Liu Z
    Curr Cancer Drug Targets; 2019; 19(1):50-64. PubMed ID: 30289077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats.
    Meregalli C; Canta A; Carozzi VA; Chiorazzi A; Oggioni N; Gilardini A; Ceresa C; Avezza F; Crippa L; Marmiroli P; Cavaletti G
    Eur J Pain; 2010 Apr; 14(4):343-50. PubMed ID: 19695912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.
    Cavaletti G; Gilardini A; Canta A; Rigamonti L; Rodriguez-Menendez V; Ceresa C; Marmiroli P; Bossi M; Oggioni N; D'Incalci M; De Coster R
    Exp Neurol; 2007 Mar; 204(1):317-25. PubMed ID: 17214983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice.
    Bruna J; Udina E; Alé A; Vilches JJ; Vynckier A; Monbaliu J; Silverman L; Navarro X
    Exp Neurol; 2010 Jun; 223(2):599-608. PubMed ID: 20188093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy.
    Zheng H; Xiao WH; Bennett GJ
    Exp Neurol; 2012 Dec; 238(2):225-34. PubMed ID: 22947198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical role of Ca
    Tomita S; Sekiguchi F; Deguchi T; Miyazaki T; Ikeda Y; Tsubota M; Yoshida S; Nguyen HD; Okada T; Toyooka N; Kawabata A
    Toxicology; 2019 Feb; 413():33-39. PubMed ID: 30552955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve.
    Quartu M; Carozzi VA; Dorsey SG; Serra MP; Poddighe L; Picci C; Boi M; Melis T; Del Fiacco M; Meregalli C; Chiorazzi A; Renn CL; Cavaletti G; Marmiroli P
    Biomed Res Int; 2014; 2014():180428. PubMed ID: 24877063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
    Dou QP; Zonder JA
    Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.
    Poruchynsky MS; Sackett DL; Robey RW; Ward Y; Annunziata C; Fojo T
    Cell Cycle; 2008 Apr; 7(7):940-9. PubMed ID: 18414063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy.
    Moschetti G; Amodeo G; Maftei D; Lattanzi R; Procacci P; Sartori P; Balboni G; Onnis V; Conte V; Panerai A; Sacerdote P; Franchi S
    J Neuroinflammation; 2019 Apr; 16(1):89. PubMed ID: 30995914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
    Yamamoto S; Egashira N
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model.
    Bruna J; Alé A; Velasco R; Jaramillo J; Navarro X; Udina E
    J Peripher Nerv Syst; 2011 Sep; 16(3):199-212. PubMed ID: 22003935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.
    Yan W; Wu Z; Zhang Y; Hong D; Dong X; Liu L; Rao Y; Huang L; Zhang X; Wu J
    Biomed Pharmacother; 2021 Oct; 142():112068. PubMed ID: 34463262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of CCL2 via ATF3/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy.
    Liu C; Luan S; OuYang H; Huang Z; Wu S; Ma C; Wei J; Xin W
    Brain Behav Immun; 2016 Mar; 53():96-104. PubMed ID: 26554515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific Attenuation of Purinergic Signaling during Bortezomib-Induced Peripheral Neuropathy In Vitro.
    Holzer AK; Suciu I; Karreman C; Goj T; Leist M
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.